Medical

Bile duct cancer is a rare but highly malignant tumour that occurs in the human bile duct system and has long had a poor prognosis. Now, researchers at University College London and University College London Hospitals, in an international multi-centre trial, have identified potentially good treatments that may radically improve the lives of some patients with bile duct cancer.

CAR-T therapy is a cellular immunotherapy treatment that has become very popular in recent years. This therapy uses genetic engineering techniques to upgrade the patient's immune T cells in vitro, before entering the body to exert a powerful anti-cancer effect. Currently, CAR-T therapy has performed very well in blood cancers such as lymphoma and leukaemia.

Researchers at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai have now identified a new treatment that promises to help cancer patients with bone marrow transplants manage side effects better than current standard therapies, making the treatment more effective and safer.

Immunotherapy has been a very important treatment in recent years, with many patients in lung cancer, malignant melanoma and many other cancers experiencing dramatic improvements in prognosis with this cutting-edge therapy. In pancreatic cancer, however, progress in immunotherapy has been very slow and its effectiveness has been extremely limited.

Communication between doctors and patients is an art, and communication between patients and doctors also requires skills. This is not only a need for interpersonal communication, but also a need for the vital interests of patients.

The US FDA approved a new treatment for non-small cell lung cancer - Tremelimumab + Durvalumab + platinum-based chemotherapy. The triple combination therapy significantly improves efficacy and patient survival and has a good safety profile.

A new clinical trial update shows that oxitinib (known as Teresa, or 9291) nearly doubled disease-free survival and halved post-operative recurrence rates in lung cancer patients carrying an early stage EGFR mutation!

For patients with relapsed and refractory multiple myeloma, the CAR-T cell therapy Ide-cel resulted in a two-fold increase in the average length of time that patients' tumours did not progress compared to standard treatment, with 71% of patients experiencing substantial tumour regression and 39% experiencing complete tumour disappearance.

The Mediterranean diet contains mono and polyunsaturated fats from olive oil nuts and fish, polyphenols and fibers from vegetables, fruits and whole grains, which are closely related to the better efficacy of immunotherapeutic drugs called immunocheckpoint inhibitors (ICI).

Data from a study recently published by the Royal Marsden Cancer Centre showed promising data for the combination of Avutometinib + Defactinib in the treatment of ovarian cancer, resulting in significant tumour shrinkage in 28% of patients and disease control in 93% of patients.